tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 6Genealiases: []
Q-omics provides the consensus-scored YWHAZP6 profile across patient tissues and cancer cell-line models. YWHAZP6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, YWHAZP6 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, YWHAZP6 RNA expression shows 17,785 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where YWHAZP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YWHAZP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YWHAZP6 survival associations across molecular data types. YWHAZP6 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YWHAZP6 RNA expression–survival associations across cancer types. High YWHAZP6 expression shows unfavorable associations in UVM, ACC, LUAD, LIHC and PAAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for YWHAZP6 RNA expression.
This table summarizes YWHAZP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for YWHAZP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YWHAZP6 shows lower tumor expression in THCA and higher tumor expression in HNSC, LUSC, LUAD, BLCA and BRCA. The HNSC box plot shows higher YWHAZP6 RNA expression in tumor versus normal tissue (log2 FC = +0.569, t-test p < 0.001).
This table shows molecular features associated with YWHAZP6 in patient tissues and cancer cell lines. In patient samples, YWHAZP6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
